Cargando…
2257. BDG-Guided Management of Empirical Antifungal Therapy: a Real-life Experience in a Hospital-Wide Context with High Incidence of Non-albicans Candida Infection
BACKGROUND: BDG-guided management of empirical antifungal therapy (AT) has been suggested as a tool to rule out invasive candidiasis (IC) and discontinue AT in critically ill patients. However, some authors reported lower BDG sensibility for non-albicans Candida (NAC) infection. Impact of BDG use in...
Autores principales: | Marconi, Lorenzo, Maccaro, Angelo, Cimatti, Matteo, Scotto, Riccardo, Venturelli, Claudia, Appolloni, Lucia, Furii, Francesca, Morotti, Marta, Puggioli, Cristina, Giannella, Maddalena, Viale, Pierluigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810797/ http://dx.doi.org/10.1093/ofid/ofz360.1935 |
Ejemplares similares
-
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
por: Whaley, Sarah G., et al.
Publicado: (2017) -
Incidence and Antifungal Susceptibility of Candida Albicans Infections
por: UNGUREANU, A., et al.
Publicado: (2016) -
Liquid and vapour-phase antifungal activities of essential oils against Candida albicans and non-albicans Candida
por: Mandras, Narcisa, et al.
Publicado: (2016) -
In Vitro Antifungal Activity of Equol against Candida albicans
por: Lee, Jeong Ah, et al.
Publicado: (2010) -
Chloroquine sensitizes biofilms of Candida albicans to antifungal azoles
por: Shinde, Ravikumar Bapurao, et al.
Publicado: (2013)